The original drug price pharmacy is 454% higher than the hospital drug price monitoring network spread

September 8, The Health Insurance Bureau of Weihai City, Shandong Province, released information on the monitoring of pharmaceutical prices in September 2020. Monitoring shows that the price of medicines in private pharmaceutical institutions is generally higher than in public hospitals, in Bayer's Moxiza star, for example, the price of drugstores is 454% higher than that of public hospitals. As more and more regional health insurance bureaus carry out drug price monitoring, drug price differences may gradually narrow, and for enterprises, the off-court market may be difficult to maintain high prices.

price monitoring led to priceWeihai City Medical Insurance Bureau said, in order to keep track of the market price of medicines and medical expenses changes, select some drugs, medical supplies, medical services prices for monitoring, published regularly every month.The comb found that the monitoring information of this issue was newly incorporated into vitamin B6, the actual price of a total of 20 kinds of drugs, involving 18 pharmaceutical institutions. From the monitoring situation: the price of drugs in private pharmaceutical institutions is higher than that of public hospitals as a whole, and the difference in drug prices is greater: Bayer's Moxishaxing (0.4g x 3) sold by Lijian Pharmacy is 73.8 yuan/box, which is 454% higher than the 13.32 yuan/box of several public hospitals. In addition, Pfizer's Atovastatin calcium tablets (20mg x 7) sold at Weihai Guanghua Hospital were 50.3 yuan/box, 17.6% higher than the 42.77 yuan/box sold at several public hospitals in Weihai City.As Weihai City has issued a number of monitoring information, monitoring results also show that some drug prices have decreased significantly. Weihai City mentioned that since the implementation of dynamic monitoring of pharmaceutical prices and "price-to-three", some private pharmaceutical institutions in a timely manner to follow the pace of price reduction in public hospitals, the current monitoring report shows that The health pharmacy sales of Sanofi's Glime tablets (2mg x 15 tablets) has been reduced from 67.5 to 55 yuan / box, a decline of 18.51%.At the end of July, Weihai City Health Insurance Bureau issued a "notice on further doing a good job in monitoring pharmaceutical prices", proposed to use (business volume) large, strong public response, high social concern, medical insurance funds affected by the price of drugs, medical supplies and medical services in a timely manner into the scope of price monitoring, expanding the monitoring object and scope, and implement dynamic adjustment. And constantly broaden the channels of information distribution, improve the public's right to know the price of medicine, guide the formation of reasonable prices and rational choice of patients.In the view of the industry, price monitoring is committed to promoting the solution of the problem of high pharmaceutical prices, "expensive to see a doctor", price monitoring is an indispensable link in the management of pharmaceutical prices, is the implementation of macro-control, strengthen the price supervision of an important basis. Through real-time monitoring of pharmaceutical prices online, the establishment of pharmaceutical price monitoring and early warning and analysis system, really squeeze drugs, medical supplies prices falsely high space.Since 2019, the state and provinces (municipalities and autonomous regions) have introduced a series of institutional measures to deepen the reform of pharmaceutical prices and promote the formation of reasonable prices. At the end of 2019, the Leading Group of the State Council on Deepening the Reform of the Medical and Health System issued a notice on a number of policy measures to further deepen the reform of the medical and health system with the centralized procurement and use of medicines as a breakthrough, stressing that the national drug price monitoring and early warning system will be improved and the dynamic monitoring of domestic procurement prices will be strengthened.Subsequently, the State Health Insurance Administration issued "on the current drug price management opinions", the existence of price increases or frequency anomalies, between regions or between the line and offline price differences, circulation links significantly exceed a reasonable level, distribution is not in place, etc. , medical security departments at all levels may consult the relevant operators, ask for written explanation of the situation;

the out-of-hospital market is difficult to sell "high-priced"Today, more and more regions are put drug price monitoring on the agenda. Recently, Hainan Province announced that it intends to launch a third-party monitoring service system for comprehensive supervision of pharmaceutical prices in the near future, officially launching third-party monitoring of pharmaceutical prices.In recent years, consumers have questioned the different prices of the same drug. Especially since the implementation of the national collection, private pharmaceutical institutions and hospitals between the formation of price inverted. Industry insiders said that after the national harvest, the previous price system will be disrupted, so the hospital and private pharmaceutical institutions between the formation of a very large price gap. Because hospital sales are cheap, this group of consumers has also returned to the hospital. In this environment, consumers also have their opinions.However, there is also a view that the large price gap between public hospitals and private pharmaceutical institutions is more difficult to balance, because public hospitals are not for-profit institutions, and the zero-plus-plus sales of drugs. And private pharmaceutical institutions to make money, with the increase in operating costs, some drugs will become negative gross margin varieties.Indeed, according to some pharmacies feedback, if the national collection of varieties failed to reduce prices in pharmacies at the same time, sales will be greatly affected. While the performance impact of the national collection, health insurance payment personal account reform is making pharmacies operating "difficult", meaning that in pharmacies, can be used for personal account purchase costs less and less, health insurance payments will return to hospitals.In the view of the industry, the national collection has a fundamental impact on the whole related variety industry involved. How to enable ordinary people to enjoy price dividends in private pharmaceutical institutions may also be the main problem that the relevant departments want to solve. On the one hand, many regions have announced that private hospitals and retail pharmacies will be included in centralized procurement, on the other hand, drug price regulation will also cover all medical institutions and pharmacies.Looking to the future, the same medicine, consumers are never willing to accept that the price gap is too large. Relevant departments are bound to further strengthen drug price management. Therefore, enterprises want to sell the same drugs at high prices in private medical institutions and pharmacies will be blocked. And private pharmaceutical institutions to join to enjoy the price dividend will be strong, but because the private pharmaceutical market usage is relatively small, private pharmaceutical institutions how to develop the market to the industry's attention, enterprises also need to re-evaluate the off-hospital market, the corresponding strategic adjustment.
(
Medical Economics Journal)
)